Aktis Oncology opens third Phase 1b trial, reports Q3 2026 resultsNov 12Quarterly updateAktis Oncology, Inc.
Novartis registers two Phase I trials: TRB191 in SCLC and XEP527 in schizophreniaNov 6Weekly roundup, 10 itemsArdtartemether and lumefantrine
Novartis posts Cosentyx nail psoriasis and imatinib results; Piqray label updatedOct 30Weekly roundup, 8 itemsalpelisibeverolimusUpdated
Novartis registers new Phase 2 NIO752 tauopathy trial; Egaten results, six studies updateOct 9Weekly roundup, 8 itemsinclisiraniptacopanUpdated
Aktis Oncology reports Q2 2026 results, three Phase 1b trials now underway or clearedAug 13Quarterly updateAktis Oncology, Inc.
FDA approves supplement 37 for Novartis's PluvictoJul 31Regulatory decisionlutetium lu 177 vipivotide tetraxetanNovartis
Novartis posts pelacarsen Phase 3 apheresis results, updates three drug labelsJul 17Weekly roundup, 8 itemscarbamazepineimatinib